Copenhagen, Denmark – October 9, 2024 – Antag Therapeutics, a leading biopharmaceutical company focused on targeting the Glucose-Dependent Insulinotropic Polypeptide (GIP) receptor to pioneernovel treatments for obesity and invested and incubated by Viva BioInnovator (VBI), today announced that the U.S. Food and Drug Administration (FDA) hasaccepted its Investigational New Drug (IND) application for its lead molecule, AT-7687. This milestoneenables Antag Therapeutics to initiate its Phase I clinical trial, which will evaluate the safety,tolerability, and pharmacokinetics of AT-7687 in both healthy lean and healthy obese subjects. Thestudy will also explore AT-7687 as a monotherapy and in combination with semaglutide, a GLP-1receptor agonist, in healthy obese individuals.
“We are thrilled to receive the FDA's acceptance of our IND application for AT-7687,” said Alexander Sparre-Ulrich, Founder & CEO of Antag Therapeutics. “This marks a major step forward in advancingour clinical development program and brings us closer to providing a potential new treatment forpatients with obesity and cardiometabolic diseases. We are excited to begin our Phase I study andfurther demonstrate the therapeutic potential of AT-7687 and GIPR antagonism.”
AT-7687 is a peptide GIP receptor antagonist designed for once-weekly subcutaneous administration.Highly translational preclinical studies have shown that AT-7687 attenuates weight gain and enhancesGLP-1-mediated weight loss while improving lipid profiles, particularly LDL, independent of weightchange. Importantly, these benefits are not associated with gastrointestinal side effects. The upcomingPhase I trial will assess safety, tolerability, and pharmacokinetics of AT-7687 alone and in combinationwith semaglutide in healthy lean and healthy obese subjects.
About AT-7687
The development of AT-7687 builds on the groundbreaking discovery of a novel human metabolite byworld-renowned Professor Jens Holst, the discoverer of GLP-1, and his colleagues. In addition topromising preclinical data, the therapeutic potential of AT-7687 is further supported by robust humangenetic validation, demonstrating that reducing GIP receptor activity is associated with leanness.
About Antag Therapeutics
Antag Therapeutics is a clinical-stage biopharmaceutical company committed to discovering anddeveloping novel therapies for obesity and cardiometabolic diseases through GIP receptorantagonism. As a pioneer in exploring the potential of GIP receptor antagonists, the company isdedicated to advancing science and improving patient outcomes by delivering groundbreakingsolutions that address unmet medical needs. For more information, please visithttps://antagtherapeutics.com.
